Adaptimmune Therapeutics logo

ADAP - Adaptimmune Therapeutics Share Price

$4.52 0.0  0.7%

Last Trade - 17/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £365.4m
Enterprise Value £286.3m
Revenue £1.44m
Position in Universe 3073rd / 6415
Bullish
Bearish
Unlock ADAP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADAP Revenue Unlock ADAP Revenue

Net Income

ADAP Net Income Unlock ADAP Revenue

Normalised EPS

ADAP Normalised EPS Unlock ADAP Revenue

PE Ratio Range

ADAP PE Ratio Range Unlock ADAP Revenue

Dividend Yield Range

ADAP Dividend Yield Range Unlock ADAP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADAP EPS Forecasts Unlock ADAP Revenue
Profile Summary

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated December 3, 2014
Public Since May 6, 2015
No. of Shareholders: 27
No. of Employees: 430
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 105,158,789
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADAP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADAP
Upcoming Events for ADAP
Similar to ADAP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.